Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice

The role of soluble TNF in tumorigenesis, distinct from transmembrane TNF, was delineated. Soluble TNF promoted chemically induced carcinogenesis and mediated the expansion of myeloid-derived suppressor cells. This pathway could serve as a potential target for cancer prevention and therapy. TNF is a potent promoter of carcinogenesis and potentially important target for cancer prevention. TNF is produced as functionally distinct transmembrane and soluble molecules (tmTNF and sTNF, respectively), but their individual roles in carcinogenesis are unexplored. We investigated the participation of tmTNF and sTNF in chemically induced carcinogenesis in mice. We found that injection of XPro1595, a dominant-negative TNF biologic (DN-TNF) and specific antagonist of sTNF, decreased tumor incidence and growth, and prolonged survival of 3-methylcholanthrene (MCA)–injected mice. Similar results were obtained following the exclusion of both TNF forms by either TNF-receptor 2–Fc fusion protein (TNFR2-Fc) treatment or TNF gene deletion. In addition, gene deletion of TNFR1, which is preferentially triggered by sTNF, was temporarily blocked, whereas gene deletion of TNFR2, which is preferentially triggered by tmTNF, enhanced MCA-induced carcinogenesis. Concomitantly with carcinogenesis induction, MCA increased circulating IL1α, accumulation of myeloid-derived suppressor cells (MDSC), STAT3 phosphorylation, and immunosuppression in the spleen. In sharp contrast, DN-TNF treatment dramatically decreased IL1α and increased the essential immunoregulatory cytokines IL1β, IL12p70, and IL17 in the peripheral blood of MCA-injected mice. In addition, MDSC accumulation, STAT3 phosphorylation, and immunosuppression in MCA-injected mice were prevented by DN-TNF treatment, TNFR2-Fc treatment, and/or gene deletion of TNF or TNFR1, but not deletion of TNFR2. These findings reveal that sTNF is both an essential promoter of carcinogenesis and a pivotal regulator of MDSCs, and indicate that sTNF could be a significant target for cancer prevention and therapy. Cancer Immunol Res; 4(5); 441–51. ©2016 AACR.

[1]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[2]  F. Pociot,et al.  Cytokine gene polymorphism in human disease: on-line databases , 1999, Genes and Immunity.

[3]  N. Mukaida,et al.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. , 2008, The Journal of clinical investigation.

[4]  M. Caligiuri,et al.  NK cell and DC interactions. , 2004, Trends in immunology.

[5]  T. Whiteside,et al.  Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. , 2002, Journal of immunology.

[6]  M. Lotze,et al.  PAMPs and DAMPs: signal 0s that spur autophagy and immunity , 2012, Immunological reviews.

[7]  N. Vujanović.  Role of TNF superfamily ligands in innate immunity , 2011, Immunologic research.

[8]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[9]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[10]  T. Whiteside,et al.  Suppression of natural killer‐cell and dendritic‐cell apoptotic tumoricidal activity in patients with head and neck cancer , 2013, Head & neck.

[11]  A. Moretta.  Natural killer cells and dendritic cells: rendezvous in abused tissues , 2002, Nature Reviews Immunology.

[12]  G. Bhagat,et al.  Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. , 2008, Cancer cell.

[13]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[14]  Y. Carmi,et al.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions , 2006, Cancer and Metastasis Reviews.

[15]  V. Cicinnati,et al.  Impact of p53‐based immunization on primary chemically‐induced tumors , 2005, International journal of cancer.

[16]  H. Harizi.  Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology , 2013, Cellular and Molecular Immunology.

[17]  J. Wolchok,et al.  Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. , 2012, Cancer journal.

[18]  P. Calder,et al.  Symposium on ’Nutrition in the post-genomic era’ Plenary session 4: Genetic variation and diet-related disease , 2002, Proceedings of the Nutrition Society.

[19]  P. Serafini.  Editorial: PGE2‐producing MDSC: a role in tumor progression? , 2010, Journal of leukocyte biology.

[20]  Peter O. Krutzik,et al.  Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[21]  Simon C Watkins,et al.  Dendritic cells and natural killer cells interact via multiple TNF family molecules , 2005, Journal of leukocyte biology.

[22]  J. D. den Boer,et al.  Tumor necrosis factor receptor cross‐talk , 2011, The FEBS journal.

[23]  Li Yang,et al.  Transforming Growth Factor B : Tumor Suppressor or Promoter ? Are Host Immune Cells the Answer ? , 2008 .

[24]  A. Komori,et al.  Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. , 1993, Cancer research.

[25]  Tak W. Mak,et al.  Regulation of tumour necrosis factor signalling: live or let die , 2015, Nature Reviews Immunology.

[26]  T. Whiteside,et al.  Innate Direct Anticancer Effector Function of Human Immature Dendritic Cells. II. Role of TNF, Lymphotoxin-α1β2, Fas Ligand, and TNF-Related Apoptosis-Inducing Ligand1 , 2002, The Journal of Immunology.

[27]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[28]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[29]  N. Popitsch,et al.  CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.

[30]  L. Alfred,et al.  Alterations in cell-mediated immune functions induced in mouse splenic lymphocytes by polycyclic aromatic hydrocarbons. , 1984, Cancer research.

[31]  A. Gambotto,et al.  Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. , 2007, Blood.

[32]  Richard A Flavell,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[33]  R. Vandenbroucke,et al.  Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. , 2011, Cytokine & growth factor reviews.

[34]  M. Sade-Feldman,et al.  Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. , 2013, Immunity.

[35]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[36]  Andrea Sobo-Vujanovic,et al.  Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells. , 2014, Cellular immunology.

[37]  H. Zhang,et al.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.

[38]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[39]  L. Zitvogel,et al.  Natural-killer cells and dendritic cells: "l'union fait la force". , 2005, Blood.

[40]  H. Schreiber,et al.  Inflammation as a tumor promoter in cancer induction. , 2004, Seminars in cancer biology.

[41]  Carlo M. Croce,et al.  Causes and Consequences of MicroRNA Dysregulation , 2012, Cancer journal.

[42]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[43]  E. El-Omar,et al.  Cancer and Inflammation: Promise for Biologic Therapy , 2010, Journal of immunotherapy.

[44]  Simon C Watkins,et al.  Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. , 2010, Blood.

[45]  Z. Qin,et al.  Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2 , 2014, The Journal of Immunology.

[46]  T. Whiteside,et al.  Nonsecretory apoptotic killing by human NK cells. , 1996, Journal of immunology.

[47]  U. Syrbe,et al.  TNF signaling drives myeloid-derived suppressor cell accumulation. , 2012, The Journal of clinical investigation.

[48]  Eugene A Zhukovsky,et al.  Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants , 2003, Science.

[49]  M. Kanda,et al.  Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. , 1999, Cancer research.

[50]  D. Carbone,et al.  Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. , 1996, Cellular immunology.

[51]  M. Marino,et al.  Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. , 1999, Cancer research.